Fierce Healthcare

Lantheus Medical Imaging Announces FDA Accepts for Review DEFINITY® Supplemental New Drug Application for Use in Stress

N. BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
Business Wire

New Lantheus Study Finds Significant Survival Benefit for Critically Ill Patients Undergoing Contrast-Enhanced Echocardiography

Transthoracic echocardiography, the most common type of echocardiogram, uses a transducer on a person’s chest to send high frequency ultrasound waves through the chest wall to the heart to create ...
Seeking Alpha

Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients

BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow ® disease ...
Business Wire

Lantheus Medical Imaging Announces FDA Approval of DEFINITY ® Label Update

DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension is an ultrasound contrast agent for use in patients with suboptimal echocardiograms (see Indications and Important Safety ...
Nasdaq

Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global ...